Veritus Research
Bayswater, Victoria, 3153, Australia
NCT Number: NCT07686484
The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants
Trial opening soon.
Get Notified18 year–55 year
All sexes
Interventional
Early Phase 1
Bayswater, Victoria, 3153, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Main inclusion criteria
Main exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Single dose HRS-3095 /placebo given orally - Dose level 1
Time frame: Day 8
Number of participants with Adverse events and Serious adverse events
Time frame: Day 4
Maximum observed plasma concentration (Cmax)
Time frame: Day 4
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀0-inf)
Time frame: Day 4
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 4
Terminal elimination half-life (t1/2)
Time frame: Day 8
Target occupancy assessment
Contact information is provided by the study sponsor or research team.
Eimy Minowa
CONTACT
Kathy You
CONTACT
Atridia Pty Ltd.
Industry
A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07642557
Chronic Disease, Chronic Spontaneous Urticaria
View Trial DetailsNCT07613866
Chronic Disease, Chronic Spontaneous Urticaria
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07402213
Chronic Disease, Chronic Spontaneous Urticaria
View Trial DetailsNCT06864507
Chronic Disease, Chronic Spontaneous Urticaria
Shanghai, Shanghai Municipality, China
View Trial Details